anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this clinical study was to evaluate the intensity and duration of postoperative pain following different final irrigation procedures. Patients who have asymptomaticdevital teeth required endodontic treatment were included in this study and routine root canal treatment procedure was applied to these teeth. All of the patients have been recruited from the Istanbul Medipol University Dental Clinics in Istanbul. Ninety asymptomatic teeth were randomly participated into 3 treatment groups in terms of intracanal medicament applied. The presence of postoperative pain was assessed after 12, 24, 48, 72 hrs and 1 week. Postoperative pain was recorded by each patient by using visual analogue pain scale. Before the treatments, the nature of the study, complications and associated risks were totally explained and written informed consent was obtained from all study participants. The patients were offered local anesthetic before the treatment start. The routine root canal treatment procedure was applied. Different final irrigation solutions applied in accordance to the manufacturers' instructions. At the end of treatment, each patient was given an evaluation sheet, explained the treatment procedure and using of visual analogue pain scales, and informed to be returned during the following one week. After one week the teeth was examined according to for pain intensity, percussion \& palpation sensitivity, swelling, analgesic intake and clinical status.
Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
Systems for managing multiple shared content objects using access tokens that cover the multiple shared content objects are disclosed. A method commences upon assigning the shared content objects to have individual permissions grantable to two or more users. A user configures a shareable unit to include attributes that describe a plurality of constituent shared content objects stored on one or more storage devices in the cloud-based storage system. An administrator or other user configures allow/deny access privileges to the shareable unit. Upon receiving a request from a user to access the shareable unit, a single access token is generated to provide access to the shared content objects that comprise the shareable unit. Ongoing access to the shareable unit is accomplished using the single access token, without the need to provision an access token or tokens pertaining to individual ones of the constituent shared content objects of the shareable unit.
BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease of vascular remodeling characterized by persistent pulmonary arterial pressure elevation, which can lead to right heart failure and premature death. Given the complex pathogenesis and poor prognosis of PAH, the identification and investigation of biomarkers become increasingly critical for advancing further understanding of the disease.
METHODS: PAH-related datasets, GSE49114, GSE180169 and GSE154959, were downloaded from the publicly available GEO database. By performing WGCNA on the GSE49114 dataset, a total of 906 PAH-related key module genes were screened out. By carrying out differential analysis on the GSE180169 dataset, a total of 576 differentially expressed genes were identified. Additionally, the GSE154959 single-cell sequencing dataset was also subjected to differential analysis, leading to the identification of 34 DEGs within endothelial cells. By taking intersection of the above three groups of DEGs, five PAH-related hub genes were screened out, namely Plvap, Cyp4b1, Foxf1, H2-Ab1, and H2-Eb1, among which H2-Ab1 was selected for subsequent experiments.
RESULTS: A SuHx mouse model was prepared using the SU5416/hypoxia method, and the successful construction of the model was evaluated through Hematoxylin-Eosin staining, hemodynamic detection, fulton index, and Western Blot (WB). The results of WB and qRT-PCR demonstrated a significant upregulation of H2-Ab1 expression in SuHx mice. Consistent with the results of bioinformatics analysis, a time-dependent increase was observed in H2-Ab1 expression in hypoxia-treated mouse pulmonary artery endothelial cells (PAECs). To investigate whether H2-Ab1 affects the development and progression of PAH, we knocked down H2-Ab1 expression in PAECs, and found that its knockdown inhibited the viability, adhesion, migration, and angiogenesis, while concurrently promoted the apoptosis of PAECs.
CONCLUSION: H2-Ab1 could regulate the proliferation, apoptosis, adhesion, migration, and angiogenesis of PAECs.
FIELD: medicine.SUBSTANCE: tissue-specific matrix is obtained by performing a perfusion washing and a decellularisation of a parenchymal organ. Herewith 60-120 minutes before the perfusion washing of the donor organ, measures to prevent intravascular blood cell aggregation and microcirculation disturbances are taken and involve the intramuscular or intravenous administration of a disaggregant or disaggregants (heparin and trental) into a donor. That is followed by an organ perfusion by administering into its vascular bed phosphate-buffered normal saline of the following composition: 138 mM NaCl, 2.67 mM KCl, 1.47 mM KHPO, 8.1 mM NaHPO, distilled water up to 1l and containing 1% serum albumin and 10-15% glycerol or 10-15% dimethyl sulphoxide with pH 7.4 in an amount equal to a double amount of the vascular bed of the organ at a perfusion pressure of 100-120 mm Hg in its arterial system. Thereafter, the decellularised organ is ground to a particle size of 0.5mm to 4mm; the ground fragments are portioned in an amount of 5-10g, and each portion is frozen by immersing into liquid nitrogen gas for 5-10 minutes. The frozen portions are re-ground to a particle size of no more than 600 mcm; then each portion is de-frozen by re-suspending in phosphate-buffered normal saline 30-70ml of the following composition containing 138 mM NaCl, 2.67 mM KCl, 1.47 mM KHPO, 8.1 mM NaHPO, distilled water up to 1l , with pH 7.4, at a room temperature. The prepared suspension is cleaned from the particles of less than 200mcm; the prepared fraction is lyophilised and sterilised to prepare the target matrix samples.EFFECT: using the invention enables providing the more complete decellularisation procedure ensured by preventing the disturbed microcirculation in the donor organ, providing higher density and uniformity of the re-cellularisation of the entire matrix and easier control thereof by increasing the matrix adhesive surface areas for the contact to inoculating cells as prepared in the form of powder.4 cl, 5 ex, 9 dwg
Biliary atresia (BA) is an idiopathic, progressive, and fatal disease if untreated. Since Kasai first introduced the operation for BA in 1959, there have been encouraging results in treating this disease. Ascending cholangitis is a frequent and often recurrent complication. It may worsen the prognosis, with an increase in mortality, secondary failure of restoration of bile flow, and possible exacerbation of portal hypertension. For patients who have had restoration of bile flow with a timely portoenterostomy, the recurrence of ascending cholangitis is the single most significant variable pertaining to long-term prognosis. Patients with multiple episodes of ascending cholangitis are more likely to require liver transplantation than those without multiple recurrences. Therefore, the prevention of cholangitis is crucial in the management of patients who have had a Kasai portoenterostomy.

Some oral antibiotics, like trimethoprim-sulfamethoxazole (TMP/SMZ) and neomycin have showed the effect to prevent against ascending cholangitis. But, we should consider the problem of drug resistance after long-term use of antibiotics. Is there any better and safer treatment? Probiotics are live microorganisms, which have beneficial effects on human health. Many studies have showed that probiotics have effects to treat or prevent intestinal infection or inflammation even for patient after liver transplantation. The aim of this study is to investigate the possibility of use of probiotics in prophylaxis of ascending cholangitis.
PURPOSE:To produce a vaccine useful in the field of stock raising and dairy farming, by inserting a gene to code an antigen protein of rinderpest virus and a virus promoter to a specific gene. CONSTITUTION:Rinderpest virus strain (L13 strain) is cultivated and treated by cloning, etc., to give a plasmid (A), a gene to code an antigen protein such as hemagglutinin (RVH) of rinderpest virus. Then, a cell derived from a desired kidney, etc., is infected with rinderpest virus CPRO6 strain, etc., and the prepared virus is treated with an enzyme to give a plasmid (B) such as pB23, a promoter of A type sealed gene of rinderpest virus. Then, vaccinia WR strain is multiplied in RK cell to give a virus, which is treated with a restriction enzyme to give a plasmid (e.g., pEWBJ-1)(C), a vaccinia gene such as thymidine kinase gene, etc. nonessential for multiplication of vaccinia virus. Then, the components A and B are inserted into the component C to give a combinant vaccinia virus (D). Then, a vaccine containing the component D is prepared.
Patients with squamous cell cancer receive standard of care chemotherapy consisting of cisplatin on days 1, 8, 29, and 36, and etoposide on days 1-5 and 29-33. Cycles repeat every 4 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell cancer receive standard of care chemotherapy consisting of cisplatin and pemetrexed on days 1, 22, and 43. Cycles repeat every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. All patients receive durvalumab IV over 1 hour Q4W. Radiation to the primary tumor will be given over 8-15 fractions during weeks 1-3 of chemotherapy. For patients who have residual disease in the mediastinal lymph nodes at week 9, radiation will be given to the lymph nodes starting week 11. Durvalumab is given for 2 years after completion of radiation in the absence of disease progression or unacceptable toxicity.
Pregnancy Category C. In an embryo-fetal study, mice have been dosed daily by subcutaneous injection with recombinant human hyaluronidase at dose levels up to 2,200,000 U/kg. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which represents several orders of magnitude over the suggested human dose range of 50-300 U of HYLENEX recombinant (0.8-5 U/kg in a 60 kg subject).

In a pre- and postnatal development study, mice have been dosed daily by subcutaneous injection with recombinant human hyaluronidase at dose levels up to 1,100,000 U/kg. The study found no adverse effects on sexual maturation, learning and memory of offspring, or their ability to produce another generation of offspring.

It is also not known whether HYLENEX recombinant can cause fetal harm when administered to a pregnant woman. HYLENEX recombinant should be given to a pregnant woman only if clearly needed.
An improved method for selectively targeting a substance either to the parenchymal cells or the non-parenchymal cells of the liver makes use of the property that there are two pathways for uptake of liposomes by the liver: a saturable pathway involving phagocytosis and mediated by the Kupffer cells, and a non-saturable pathway involving pinocytosis and mediated by the parenchymal cells. The substance to be targeted is administered in carrier liposomes having a diameter of less than about 200 nm and a half-life in the circulation of at least about 5 hours as measured at an injection dose of about 30-50 micrograms of lipid per gram of body weight. The substance can be targeted to the parenchymal cells by administering it in carrier liposomes at a liposomal lipid dose expressed in micrograms of lipid per gram of body weight at least equal to a critical liposomal lipid dose, typically about 7 micrograms per gram of body weight to about 10 micrograms per gram of body weight. The substance can also be targeted to the parenchymal cells by selectively blocking the saturable pathway by the action of a blocking agent. The substance can be targeted to the non-parenchymal cells by administering it in carrier liposomes at a dose sufficiently lower than the critical lipid dose, typically 0.30  mu g of lipid per gram of body weight or less. The substance can be a polypeptide, a polynucleotide, a carbohydrate, or a drug, such as an antiviral drug.
The active ingredient in gabapentin capsules is gabapentin, which has the chemical name 1-(aminomethyl) cyclohexaneacetic acid. The molecular formula of gabapentin is C9H17NO2 and the molecular weight is 171.24. The structural formula of gabapentin is:   


Gabapentin is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25.

Each gabapentin capsule contains 100 mg, 300 mg, or 400 mg of gabapentin and the following inactive ingredients: anhydrous lactose, cornstarch, and talc. The 100 mg capsule shell contains gelatin, sodium lauryl sulfate, and titanium dioxide. The 300 mg capsule shell contains gelatin, sodium lauryl sulfate, titanium dioxide, and yellow iron oxide. The 400 mg capsule shell contains gelatin, sodium lauryl sulfate, red iron oxide, titanium dioxide, and yellow iron oxide. The imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propyl glycol, strong ammonia solution, and titanium dioxide.
PROBLEM TO BE SOLVED: To prepare a paper-like cosmetic giving natural finishes, not causing irregular coloration, color darkening and irregularity, also not causing messy makeup with time, excellent in usability, and also excellent in a UV light- preventing effect, safety and stability. SOLUTION: This paper-like cosmetic contains 80-99wt.% of a powdery component (e.g. talc) and 1-20wt.% of non-collapslble resin capsules having an average particle diameter of 0.1-20μm, encapsulating a UV light-preventing agent and containing a resin not dissolving the UV light-preventing agent as capsule membranes. The UV light-preventing agent includes a UV light absorbent (e.g. 2-ethylhexyl para-dimethylaminobenzoate) and a UV light-reflecting or absorbing powdery material (e.g. titanium dioxide). The resin used for forming the non-collapslble resin capsules includes methyl methacrylate resin, etc., and used for forming the non-collapsible resin capsules by a known method.  The cosmetic components are dispersed in water or a water-containing alcohol, coated on exclusive paper and subsequently dried to prepare the paper-like cosmetic such as paper-like face powder, paper-like foundation, paper-like eye shadow or paper-like cheek rouge.
<P>PROBLEM TO BE SOLVED: To provide a compound capable of controlling activity in a CXC-chemokine receptor.  <P>SOLUTION: There are disclosed novel compounds of formula (IA), and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising substituent B include aryl and heteroaryl. Also there is disclosed a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.  <P>COPYRIGHT: (C)2011,JPO&INPIT
These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
The virtual reality sedation-analgesia solution developed by Deepsen combines 3D environment content with medical hypnosis techniques. The technology includes a wearable visual headset that contains head movement sensors, enabling patient interaction in the virtual environment, as well as isolating headphones.
Gabapentin IR is the immediate release form of the medication. Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week. Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15). Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
Serious, life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status [see Overdosage (10.2)]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of opioids, the risk is greatest during initiation of therapy or following a dose increase. Monitor patients closely for respiratory depression, especially when initiating therapy with OLINVYK and following dosage increases.

To reduce the risk of respiratory depression, proper dosing of OLINVYK is essential [see Dosage and Administration (2)]. Overestimating the OLINVYK dosage when converting patients from another opioid product can result in fatal overdose with the first dose. 

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper.
A method of preparing sunscreens in which a dispersion of zinc oxide particles in an oil is formed by milling in the presence of a particulate grinding medium and mixed with cosmetically acceptable materials is claimed. The particles of zinc oxide have an average size of from 0.005 to 0.15 micron and the dispersion is substantially transparent to visible light but with an extinction coefficient at 308 nm (E(308)) and at 360 nm (E(360)) of at least 9 litres per gram per centimetre. The ratio E(360):E(308) is in the range 0.75:1 to 1.5:1. In a preferred method a mixed dispersion containing titanium dioxide and zinc oxide, having E(308) at least 15 litres per gram per centimetre, E(360) at least 10 litres per gram per centimetre and the ratio E(360):E(308) in the range 0.3:1 to 1.5:1 is used. The mixed dispersion is also claimed. The sunscreens prepared have a good balance of absorption for UVA and UVB radiation and better SPF values than those prepared from titanium dioxide and/or zinc oxide powders.
The participants received online delivered (over zoom) group based exercise classes (2x/wk for first 2 weeks; 1x/wk for the remaining weeks) followed by a 15 minute post workout social session. Participants also participants received a PDF of a home-based exercise program with embedded videos and a Garmin Vivosmart4 activity tracker. The accelerometer is not intended to be an active part of the intervention but is used to gather an objective measure of PA levels.
The FDA cleared Angel® Concentrated Platelet Rich Plasma System and Angel® cPRP Processing Set will be used to process the PRP. The targeted final PRP volume of 6 ml will be injected in up to 4 facet joints (2 levels) at 1.5 ml per joint.
Provided is an antibody that specifically binds human av(3(3 and blocks binding of TGFp peptide to av(38, wherein the antibody binds to the specificity determining loop (SDL) of human (38. In some embodiments, the antibody further binds to one, two, or all three of the human av-head domain, the al helix of human (38, or the al helix of human (38. In some embodiments, the antibody is humanized or chimeric. In some embodiments, the antibody is linked to a detectable label. Also provided is a method of enhancing an immune response in a human individual, comprising administering a sufficient amount of the antibody to the individual, thereby enhancing an immune response. Also provided are pharmaceutical compositions comprising the anti-av1313 antibodies or antigen-binding molecules thereof
The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
With regard to the Kinesiotape technique, 2 I-shaped tapes were placed at the quadriceps, following the same direction of the muscle fibres and with no tension. At the gluteus, 2 I-shaped tapes were applied following the same direction of the muscle fibres and with no tension.
The invention relates to sequences, a preparation method and application of two types of hylarana guentheri antibacterial peptides. The two types of antibacterial peptides are separated from skin secreta of hylarana guentheri, and antibacterial and hemolytic activities of the antibacterial peptides are detected; a secondary structure of the antibacterial peptides under a simulated film environment is researched. The two antibacterial peptides are obtained: the antibacterial peptide A with an amino acid sequence shown as SEQ ID NO.1; the antibacterial peptide B with an amino acid sequence shown as SEQ ID NO.2. The antibacterial peptide A provided by the invention has an inhibition effect on staphylococcus aureus, colon bacillus and bacillus subtilis; the antibacterial peptide B has a very good sterilization effect on the bacillus subtilis and the staphylococcus aureus. The two types of antibacterial peptides, provided by the invention, have the characteristics of novel structure, strong antibacterial activities and the like, and have an important value in the aspects of medicine development and application. The sequences, the preparation method and the application of two types of the hylarana guentheri antibacterial peptides have important meanings on researches of an antibacterial mechanism of the antibacterial peptides, and further improvement, and development and utilization of the antibacterial peptides.